Novo Nordisk and Vivtex Partner to Craft Oral Peptide Medicine Formulations
Novo Nordisk entered a collaboration with Vivtex to develop oral formulations of peptide-based medicines. The deal combines Novo Nordisk’s therapeutic pipeline with Vivtex’s proprietary absorption-enhancement technology to enable oral delivery of drugs currently limited to injectable administration.
1. Collaboration Overview
On February 26, 2026, Novo Nordisk and Vivtex initiated a research collaboration focused on co-developing oral formulations of peptide-based drug candidates. The agreement leverages Novo Nordisk’s clinical development expertise alongside Vivtex’s specialized drug delivery platform.
2. Vivtex Oral Delivery Technology
Vivtex contributes its proprietary absorption-enhancement technology designed to improve bioavailability of large-molecule drugs when administered orally. The platform employs advanced excipients and formulation methods to protect peptides from gastrointestinal degradation and facilitate intestinal uptake.
3. Potential Pipeline Benefits
Successful oral versions of existing injectable therapies could broaden patient access and adherence in chronic treatment areas. The initiative may strengthen Novo Nordisk’s competitive position in the emerging market for oral peptide therapeutics.